Biotech Thrives Despite Arid Equity Market

Compiled By Deborah Austin Bucking a tough equity market, 2001 ranked as second-best financing year in the biotechnology sector's 30-year history -- with $12.9 billion invested -- says San Francisco-based life sciences merchant bank Burrill & Co. ...
Jan. 13, 2005
Compiled ByDeborah Austin Bucking a tough equity market, 2001 ranked as second-best financing year in the biotechnology sector's 30-year history -- with $12.9 billion invested -- says San Francisco-based life sciences merchant bank Burrill & Co. Biotech raised $4.6 billion in a vigorous fourth-quarter post-Sept. 11 rebound, doubling the third quarter's $2.2 billion. The upward trend likely will continue, says Burrill & Co. CEO G. Steven Burrill. "We've seen a flurry of M&A activity, the IPO window has reopened a little, and the venture-capital community has again developed an appetite for life-sciences deals," Burrill says. Also, he notes, the biotechnology industry has become creative in financing itself, using convertible debt, shelf registrations and PIPEs (Private Investment in a Public Entity). Meanwhile, a new subindustry has emerged: biodefense. Following Sept. 11 and the anthrax scares, stock prices have risen for many biotech firms involved in the manufacture of products ranging from portable contaminant-detection devices to edible vaccines. The best-ever financing year for biotechnology occurred in 2000, when $32 billion was raised. Burrill predicted that the biotechnology sector may raise as much as $20 billion in 2002.
Sign up for IndustryWeek Newsletters
Get the latest news and updates.

Voice Your Opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!